Antagonism action of E. coli strain Nissle 1917
- E. coli strain Nissle 1917 suppresses the multiplication of pathogenic microorganisms and protects against the invasion of enteric pathogenic microorganisms, e. g. EHEC 18; 19; 28 as well as the potential adverse effects of a preceding intestinal infection (post-infectious irritable bowel syndrome).29
Furthermore:
- E. coli strain Nissle 1917 has a direct stimulating effect on the smooth musculature of the intestines.30
- E. coli strain Nissle 1917 reduces the mutagenic activity of various potentially carcinogenic compounds.31
- An increased COX-2-activity, often brought in connection with inflammatory bowel diseases or the development of colonic carcinoma, and thus increased prostaglandin E2-levels, are decreased in vitro in the presence of E. coli strain Nissle 1917.32
18) Leatham MP et al. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect Immun 2009; 77: 2876–2886.
19) Reissbrodt R et al. Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol Lett 2009; 290: 62–69.
28) Rund SA et al. Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7. Int J Med Microbiol 2013; 303: 1–8.
29) Kruis W et al., A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27(4): 467–474.
30) Bär F et al. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009; 21: 559-e17.
31) Sonnenborn U et al. Antimutagenic activity of the probiotic E. coli strain Nissle 1917. J Crohns Colitis 2009; 3: S136.
32) Otte JM et al. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 2009; 61(1): 103–113.